TELA

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 21

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,453,593

F36 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $12.00 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F37 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 12,941 shares of the amount shown above and EW Fund 2-A purchased 18,884 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 20

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,421,768

F35 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 3,009 shares of the amount shown above and EW Fund 2-A purchased 4,391 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 19

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,414,368

F33 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.34 to $12.40 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F34 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 5,124 shares of the amount shown above and EW Fund 2-A purchased 7,476 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 18

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,401,768

F32 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 4,066 shares of the amount shown above and EW Fund 2-A purchased 5,934 shares of the amount shown above.

SEC source: 0001192482-20-000451 · edgar.xml · derivative · entry 1

O'Brien Federica F. · CIK 0001140119 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001192482-20-000450 · edgar.xml · derivative · entry 1

Oliva Adele C · CIK 0001339379 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001192482-20-000452 · edgar.xml · derivative · entry 1

COLLERAN LISA N · CIK 0001212312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001192482-20-000447 · edgar.xml · derivative · entry 1

EVANS DOUGLAS G · CIK 0001225164 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001192482-20-000448 · edgar.xml · derivative · entry 1

Burgess Vincent J · CIK 0001365408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001192482-20-000449 · edgar.xml · derivative · entry 1

Azarbarzin Kurt · CIK 0001792303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,806

Underlying: Common Stock · 8,806 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 17

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,391,768

F31 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 2,033 shares of the amount shown above and EW Fund 2-A purchased 2,967 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 16

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,386,768

F29 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F30 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 6,099 shares of the amount shown above and EW Fund 2-A purchased 8,901 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 15

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,371,768

F27 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.08 to $9.19 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F28 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 4,066 shares of the amount shown above and EW Fund 2-A purchased 5,934 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 14

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,361,768

F26 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 1,235 shares of the amount shown above and EW Fund 2-A purchased 1,802 shares of the amount shown above.

SEC source: 0001192482-20-000302 · edgar.xml · derivative · entry 1

COLLERAN LISA N · CIK 0001212312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2030-04-20

F1 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of April 20, 2020, subject to the Reporting Person's continuous service with the Issuer.

SEC source: 0001192482-20-000303 · edgar.xml · derivative · entry 1

EVANS DOUGLAS G · CIK 0001225164 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2030-04-20

F1 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of April 20, 2020, subject to the Reporting Person's continuous service with the Issuer.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 13

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,358,731

F24 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.14 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F25 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 2,846 shares of the amount shown above and EW Fund 2-A purchased 4,154 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 12

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,351,731

F22 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.18 to $8.29 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F23 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 10,166 shares of the amount shown above and EW Fund 2-A purchased 14,834 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 11

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,326,731

F20 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.99 to $8.02 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F21 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 7,116 shares of the amount shown above and EW Fund 2-A purchased 10,384 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 10

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,309,231

F18 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.97 to $8.00 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F19 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 5,083 shares of the amount shown above and EW Fund 2-A purchased 7,417 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 9

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,296,731

F16 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.05 to $8.09 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F17 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 6,099 shares of the amount shown above and EW Fund 2-A purchased 8,901 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 8

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,281,731

F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.93 to $8.00 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F15 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 4,066 shares of the amount shown above and EW Fund 2-A purchased 5,934 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 7

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,271,731

F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.35 to $8.58 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F13 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 10,166 shares of the amount shown above and EW Fund 2-A purchased 14,834 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 6

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,246,731

F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.36 to $8.38 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 6,099 shares of the amount shown above and EW Fund 2-A purchased 8,901 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 5

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,231,731

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.98 to $8.39 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 8,133 shares of the amount shown above and EW Fund 2-A purchased 11,867 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 4

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,211,731

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.16 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 7,265 shares of the amount shown above and EW Fund 2-A purchased 10,601 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 3

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,193,865

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.02 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 3,917 shares of the amount shown above and EW Fund 2-A purchased 5,717 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 2

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,184,231

F3 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Fund 2 and EW Fund 2-A on the date set forth above. EW Fund 2 purchased 6,099 shares of the amount shown above and EW Fund 2-A purchased 8,901 shares of the amount shown above.

SEC source: 0000950170-24-016357 · ownership.xml · nonDerivative · entry 1

EW HEALTHCARE PARTNERS FUND 2, L.P. · CIK 0001746777 · 10% owner · See Remarks

EW HEALTHCARE PARTNERS FUND 2-A, L.P. · CIK 0001746779 · 10% owner · See Remarks

EW Healthcare Partners Fund 2 GP, L.P. · CIK 0001793943 · 10% owner · See Remarks

EW Healthcare Partners Fund 2-UGP, LLC · CIK 0001793948 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Remarks

Disclosed balance after: 1,169,231

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.56 per share, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: The share total shown above is the aggregate amount of shares purchased by EW Healthcare Partners Fund 2, L.P. ("EW Fund 2") and EW Healthcare Partners Fund 2-A, L.P. ("EW Fund 2-A," and together with EW Fund 2, the "EW Funds"), on the date set forth above. EW Fund 2 purchased 6,099 shares of the amount shown above and EW Fund 2-A purchased 8,901 shares of the amount shown above.

SEC source: 0001192482-20-000068 · edgar.xml · derivative · entry 1

Murphy Peter C. · CIK 0001801542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-01-27

F1 · derivative.exercise_date: The option vests 25% on January 27, 2021, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer.

SEC source: 0001493152-19-019419 · ownership.xml · nonDerivative · entry 1

RTW INVESTMENTS, LP · CIK 0001493215 · 10% owner

WONG RODERICK · CIK 0001493280 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By RTW

Disclosed balance after: 1,139,358

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-19-019380 · ownership.xml · nonDerivative · entry 1

RTW INVESTMENTS, LP · CIK 0001493215 · 10% owner

WONG RODERICK · CIK 0001493280 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By RTW

Disclosed balance after: 1,175,358

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.

SEC source: 0001192482-19-000419 · edgar.xml · derivative · entry 7

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 758,623

Underlying: Common Stock · 30,725 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000419 · edgar.xml · derivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 758,623 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000419 · edgar.xml · derivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 977,820 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000419 · edgar.xml · derivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 481,095 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000419 · edgar.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,027,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · balance_after: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000419 · edgar.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,049,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · balance_after: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 7

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,813

Underlying: Common Stock · 18,096 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

SEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 6

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 446,813 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

SEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 5

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 516,947 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 4

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 345,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 3

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,751,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 2

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,234,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 6

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,931

Underlying: Series B Preferred Stock · 523 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

SEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 5

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 12,931 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

SEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 4

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,760 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 3

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,999 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000423 · edgar.xml · nonDerivative · entry 2

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,887

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001192482-19-000423 · edgar.xml · nonDerivative · entry 1

PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · balance_after: Reflects 15,572 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).